Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.
The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.
Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.
Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.
The University of California has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to cAMP-dependent protein kinase catalytic subunit α (PRKACA) targeting moiety through a linker.
Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.
Impact Therapeutics (Shanghai) Inc. has prepared and tested Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.
Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity in human induced pluripotent stem cell (iPSC)-derived sensory neurons.
RSS
